Literature DB >> 16055672

Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.

Gunamani Sithanandam1, George T Smith, Janet R Fields, Laura W Fornwald, Lucy M Anderson.   

Abstract

In many human lung adenocarcinoma cell lines, a pathway involving epidermal growth factor receptor (EGFR), ErbB2 and ErbB3 receptors, phosphatidyl inositol 3-kinase (PI3K), Akt, glycogen synthase kinase 3-beta (GSK3-beta), and cyclin D1 controls cell growth, survival, and invasiveness. We have investigated this pathway in paired transformed/nontransformed cell lines from murine peripheral lung epithelium, E9/E10 and A5/C10. The E9 and A5 carcinoma lines expressed ErbB3 and transforming growth factor-alpha (TGF-alpha) and responded to TGF-alpha stimulation with protein complex formation including the p85 regulatory subunit of PI3K, activation of Akt, phosphorylation of GSK3-beta, and increased cyclin D1 protein and the cell cycle. ErbB3 and TGF-alpha were not detected in the nontransformed E10 and C10 cell lines. Nevertheless, exposure of E10 or C10 cells to TGF-alpha activated PI3K and Akt and increased cyclin D1 and cell growth. The effector pathway from the EGFR to PI3K in these nontransformed cells included the adaptor Grb2, the docking protein Gab1, and the phosphatase Shp2. Gab1 was highly expressed in E10 and C10 cells but not in the malignant E9 and A5 sister lines. Complexes of EGFR/Grb2/Gab1/Shp2 after TGF-alpha stimulation were prominent only in E10 and C10 cells. Thus, alternate pathways downstream of EGFR regulate mitosis in these paired malignant versus nontransformed lung cell lines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055672      PMCID: PMC2715357          DOI: 10.1165/rcmb.2005-0049OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  50 in total

1.  Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1.

Authors:  Miriam Gensler; Marcus Buschbeck; Axel Ullrich
Journal:  J Biol Chem       Date:  2003-12-02       Impact factor: 5.157

2.  Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.

Authors:  Amy E Moran; Daniel H Hunt; Sara H Javid; Mark Redston; Adelaide M Carothers; Monica M Bertagnolli
Journal:  J Biol Chem       Date:  2004-08-04       Impact factor: 5.157

3.  Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.

Authors:  Anne S Tsao; Timothy McDonnell; Stephen Lam; Joe B Putnam; Nebiyou Bekele; Waun Ki Hong; Jonathan M Kurie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-07       Impact factor: 4.254

4.  Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.

Authors:  James G Jackson; Patricia St Clair; Mark X Sliwkowski; Michael G Brattain
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

5.  Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway.

Authors:  Gunamani Sithanandam; George T Smith; Akira Masuda; Takashi Takahashi; Lucy M Anderson; Laura W Fornwald
Journal:  Carcinogenesis       Date:  2003-08-01       Impact factor: 4.944

6.  Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.

Authors:  Raffaella Sordella; Daphne W Bell; Daniel A Haber; Jeffrey Settleman
Journal:  Science       Date:  2004-07-29       Impact factor: 47.728

7.  Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC.

Authors:  Toru Mukohara; Shinzoh Kudoh; Kuniomi Matsuura; Setsuko Yamauchi; Tatsuo Kimura; Naruo Yoshimura; Hiroshi Kanazawa; Kazuto Hirata; Kiyotoshi Inoue; Hideki Wanibuchi; Shoji Fukushima; Junichi Yoshikawa
Journal:  Anticancer Res       Date:  2004 Jan-Feb       Impact factor: 2.480

8.  Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.

Authors:  Gurpreet S Kapoor; Yi Zhan; Gibbes R Johnson; Donald M O'Rourke
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

9.  Keratinocyte growth factor stimulates alveolar type II cell proliferation through the extracellular signal-regulated kinase and phosphatidylinositol 3-OH kinase pathways.

Authors:  Joshua Portnoy; Douglas Curran-Everett; Robert J Mason
Journal:  Am J Respir Cell Mol Biol       Date:  2004-01-23       Impact factor: 6.914

10.  Role of the Grb2-associated binder 1/SHP-2 interaction in cell growth and transformation.

Authors:  Marina Holgado-Madruga; Albert J Wong
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  14 in total

1.  Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.

Authors:  Shigeyuki Magi; Kazunari Iwamoto; Noriko Yumoto; Michio Hiroshima; Takeshi Nagashima; Rieko Ohki; Amaya Garcia-Munoz; Natalia Volinsky; Alexander Von Kriegsheim; Yasushi Sako; Koichi Takahashi; Shuhei Kimura; Boris N Kholodenko; Mariko Okada-Hatakeyama
Journal:  J Biol Chem       Date:  2017-12-12       Impact factor: 5.157

2.  RNA interference against hepatic epidermal growth factor receptor has suppressive effects on liver regeneration in rats.

Authors:  Shirish Paranjpe; William C Bowen; George C Tseng; Jian-Hua Luo; Anne Orr; George K Michalopoulos
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

3.  ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.

Authors:  Xiaoling Song; Pang-Dian Fan; Amlak Bantikassegn; Udayan Guha; David W Threadgill; Harold Varmus; Katerina Politi
Journal:  Cancer Res       Date:  2015-01-16       Impact factor: 12.701

4.  Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts.

Authors:  Gunamani Sithanandam; Laura W Fornwald; Janet R Fields; Nicole L Morris; Lucy M Anderson
Journal:  Int J Cancer       Date:  2011-05-28       Impact factor: 7.396

5.  Biphasic regulation of ENaC by TGF-{alpha} and EGF in renal epithelial cells.

Authors:  Lian Liu; Billie Jeanne Duke; Bela Malik; Qiang Yue; Douglas C Eaton
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-18

6.  Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.

Authors:  Ying-Xin Fan; Lily Wong; Michael P Marino; Wu Ou; Yi Shen; Wen Jin Wu; Kwok-Kin Wong; Jakob Reiser; Gibbes R Johnson
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

7.  HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.

Authors:  Ana Ruiz-Saenz; Courtney Dreyer; Marcia R Campbell; Veronica Steri; Nate Gulizia; Mark M Moasser
Journal:  Cancer Res       Date:  2018-05-14       Impact factor: 12.701

Review 8.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

9.  Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth.

Authors:  M Mouradian; K D Kikawa; E D Johnson; K L Beck; R S Pardini
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2013-12-11       Impact factor: 4.006

10.  Non-coding rRNA-mediated preferential killing in cancer cells is enhanced by suppression of autophagy in non-transformed counterpart.

Authors:  C J Hwang; J R Fields; Y-H Shiao
Journal:  Cell Death Dis       Date:  2011-12-08       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.